Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
1.66(c) 1.7(c) 1.68(c) 1.68(c) 1.7(c) Last
3 994 589 1 762 207 1 904 421 576 185 867 302 Volume
+7.79% +2.41% -1.18% 0.00% +1.19% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -23,5 M
Net income 2017 -25,6 M
Debt 2017 -
Yield 2017 -
Sales 2018 9,72 M
EBIT 2018 -21,7 M
Net income 2018 -22,3 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 14,5x
Capitalization 141 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating : -
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
03/15 Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial..
03/15 CATALYST PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
03/15 NETWORKNEWSBREAKS – CATALYST P : CPRX) Shares Rally on Positive Data from ..
03/15 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Other Events
03/15 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
03/15 Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored ..
03/10 Catalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference
03/09 Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference ..
02/27 Catalyst Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement..
02/22 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files SEC Prospectus
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/21Catalyst Pharmaceuticals given $3.00 PT by Roth Capital. buy rating.  
03/21How To Profit From These Stocks: $CPRX $MDCO  
03/21Catalyst Pharmaceuticals's buy rating reiterated at HC Wainwright. $6.00 PT. .. 
03/16How To Profit From These Stocks: $CBR $CPRX  
03/15Member Video: #1357 $SNAP Gap Down Reversal $VAC $CERU $OCRX $CPRX Nails  
More tweets
Qtime:28
News from SeekingAlpha
03/16 HEALTHCARE - TOP 5 GAINERS / LOSERS : 20
03/16 Catalyst Pharmaceutical Partners' (CPRX) CEO Pat McEnany on Q4 2016 Results -..
03/15 Catalyst Pharmaceutical beats by $0.02
03/15 Midday Gainers / Losers
03/15 HEALTHCARE- TOP 5 GAINERS / LOSERS A : 15 pm
Advertisement
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Full-screen chart
Technical analysis trends CATALYST PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 4,44 $
Spread / Average Target 161%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICA..61.90%141
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results